title: Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis.
abstract: Sulfasalazine has long been used for the treatment of rheumatoid arthritis and is often chosen as a first-line treatment. Here, we report a case of sulfasalazine-induced autoimmune thrombocytopenia and review the mechanisms behind drug-induced immune thrombocytopenia (DITP) and the approach to its diagnosis and management.
authors: Nuffield Orthopaedic Centre, Headington, Oxford, UK. nehal.narayan@ndorms.ox.ac.uk.
authors: Nehal
authors: N
authors: Narayan
authors: Warwick Hospital, Warwick, UK.
authors: Shirley
authors: S
authors: Rigby
authors: Nuffield Orthopaedic Centre, Headington, Oxford, UK.
authors: Francesco
authors: F
authors: Carlucci
mesh_terms: D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D001792:Blood Platelets / Q000187:drug effects; D006801:Humans; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced* / Q000150:complications; D012074:Remission Induction; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D012460:Sulfasalazine
keywords: Autoantibodies; Blood platelets disorders; Hematologic diseases; Rheumatic diseases; Rheumatoid arthritis (RA); Thrombocytopenia; Tissues or models